Xtl Biopharmaceuticals (XTLB) Revenue (QoQ) (2011 - 2018)
Xtl Biopharmaceuticals (XTLB) Revenue (QoQ) (2011 - 2018) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 2,929.41% |
| Jun 30, 2018 | -96.11% |
| Sep 30, 2017 | -214.27% |
| Jun 30, 2017 | 42.07% |
| Sep 30, 2014 | -24.47% |
| Jun 30, 2014 | -35.26% |
| Mar 31, 2014 | -17.44% |
| Dec 31, 2013 | 50.32% |
| Sep 30, 2013 | -7.62% |
| Jun 30, 2013 | -23.92% |
| Mar 31, 2013 | 13.11% |
| Dec 31, 2012 | 73.47% |
| Sep 30, 2012 | -38.64% |
| Jun 30, 2012 | -13.33% |
| Mar 31, 2012 | -12.13% |
| Dec 31, 2011 | 38.75% |
| Sep 30, 2011 | -34.20% |